Reports Q2 revenue $153.1M, consensus $150.09M. “While it’s a challenging macro environment, we saw strong demand for spatial and single cell consumables this quarter, fueled by significant product launches earlier this year,” said Serge Saxonov, Co-founder and CEO. “We remain confident in the strength, differentiation and long-term potential of our platforms as we evolve our commercial organization and continue to execute our strategy.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics Reports Second Quarter 2024 Financial Results
- 10x Genomics announces involvement in TenK10K
- Cathie Wood’s ARK Investment buys 392.5K shares of 10x Genomics today
- Cathie Wood’s ARK Investment buys 122K shares of 10x Genomics today
- 10x Genomics price target lowered to $32 from $50 at Canaccord